Targets › SERPING1
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 3; Cardiovascular, Immunology, Genitourinary; next expected readout Dec 2026.
Serine protease inhibitor, which acrs as a regulator of the classical complement pathway. Forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. (UniProt, P05155)
Open in Phaseline: the race on SERPING1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Octapharma | OCTA-C1-INH C1 esterase inhibitor (C1-INH) protein replacement | SERPING1 | Phase 3 | Acute Hereditary Angio Edema | Dec 2026 |
| Haaglanden Medical Centre | Conestat Alfa Plasma protease C1 inhibitor exogenous protein | SERPING1 | Phase 2 | Subarachnoid Hemorrhage, Aneurysmal | Mar 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Conestat Alfa Plasma protease C1 inhibitor exogenous protein | SERPING1 | Phase 2 | Kidney Transplant | May 2031 |
Subarachnoid Hemorrhage, Aneurysmal (1) Acute Hereditary Angio Edema (1) Kidney Transplant (1)
protein or peptide (2), small molecule (1)
Haaglanden Medical Centre (1) Octapharma (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.